Logo 1200x628.jpg
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
July 30, 2024 02:00 ET | CytoSorbents
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"
Logo 1200x628.jpg
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
July 29, 2024 08:00 ET | CytoSorbents
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"
Mordor Intelligence Logo_Comp.png
Global Commercial Aviation Market to register a CAGR of 7.65% during 2023 - 2028 - Market Size, Share, Forecasts & Trends Analysis Report by Mordor Intelligence
March 16, 2023 09:00 ET | Mordor Intelligence
Hyderabad, March 16, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled “Global Commercial Aviation Market Share (2023-2028)”, the commercial aviation industry is expected to...
Aprea logo 445pt.png
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
January 11, 2023 08:00 ET | Aprea Therapeutics
DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
Aprea logo 445pt.png
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
November 09, 2022 16:15 ET | Aprea Therapeutics
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...
Aprea logo 445pt.png
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
September 08, 2022 08:00 ET | Aprea Therapeutics
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
ProLynx announces al
ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer
April 10, 2018 09:00 ET | ProLynx LLC
SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Prolynx LLC (San Francisco, CA) announced it received a Notice of Allowance for its DNA damage enhancer PLX038 (PEG~SN-38), currently in Phase 1...
Forecast International Predicts $213 Billion Regional Market Over 15 Years
September 26, 2017 03:00 ET | Forecast International
NEWTOWN, Conn., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Forecast International projects that a total of 5,728 regional aircraft will be produced in the 15-year period from 2017 through 2031, including...
Forecast International, Inc. Logo
Forecast International Predicts Restrained Growth in Regional Aircraft Market
October 03, 2013 10:46 ET | Forecast International, Inc.
NEWTOWN, Conn., Oct. 3, 2013 (GLOBE NEWSWIRE) -- In Forecast International's new study, "The Market for Regional Transport Aircraft," the Connecticut-based market research firm predicts that 4,035...
Practical Law Company & Goodwin Procter LLP to Present Free Webinar, "Affiliate Transaction Restrictions for Banks: Your Guide to the Requirements"
October 26, 2011 08:30 ET | Practical Law Company
NEW YORK, NY--(Marketwire - Oct 26, 2011) - Recognizing that even seasoned banking and finance attorneys may still struggle to understand affiliate transaction restrictions (ATRs) for banks,...